Ligand Pharmaceuticals Hits New 52-Week High of $320.93

Ligand Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 320.93 on June 30, 2026. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 3,898 million. Over the past year, Ligand Pharmaceuticals has demonstrated remarkable growth, with a staggering 297.45% increase in stock price compared to the S&P 500's 20.86% performance. The company has reported positive results for the last three consecutive quarters, showcasing an operating cash flow of USD 123.57 million and a net profit of USD 36.68 million, which has grown by 157.25%. With a price-to-earnings ratio of 68.00 and a price-to-book ratio of 3.83, Ligand Pharmaceuticals maintains an attractive valuation. Additionally, the company is net-debt free and boasts a return on equity of 5.61%. The stock's performance has been bolstered by high institutional holdings at 100%, indicating strong confidence in its fundamentals.